Renso, R., Aroldi, A., Pioltelli, P., Gambacorti-Passerini, C., Elli, E. (2018). Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. BLOOD CANCER JOURNAL, 8(6), 56 [10.1038/s41408-018-0091-6].

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

Aroldi, Andrea;Pioltelli, Pietro;Gambacorti-Passerini, Carlo;
2018

Articolo in rivista - Articolo scientifico
Hematology; Oncology; busulfan; thrombocythemia; myeloproliferative neoplasm
English
2018
8
6
56
56
open
Renso, R., Aroldi, A., Pioltelli, P., Gambacorti-Passerini, C., Elli, E. (2018). Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. BLOOD CANCER JOURNAL, 8(6), 56 [10.1038/s41408-018-0091-6].
File in questo prodotto:
File Dimensione Formato  
10281-216960.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 297.19 kB
Formato Adobe PDF
297.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/216960
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
Social impact